New protease-activated imaging agent successfully fluoresces tumors

January 7, 2016

Work is underway around the world to better localize and visualize cancer cells using fluorescence. Now, researchers at Duke Medicine report they have tested the first fluorescent imaging agent activated by a protease enzyme and proven safe in humans.

The team found the injectable liquid, LUM015, aided the detection and margin assessment of cancerous tissue in 15 patients undergoing surgery for soft-tissue sarcoma or breast cancer.

Their study was published online Jan. 6 in  Science Translational Medicine.

Read the full article.